Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InterMune Gets Ready To Go Commercial With Esbriet Launch In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

InterMune plans to launch the first drug for IPF in Europe in September, and has initiated a new Phase III trial with the aim of securing U.S. approval in 2014.

You may also be interested in...



After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market

In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.

Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging

A wave of biotechs is making the milestone move from drug developer to drug marketer, but investors are less interested than ever in sticking around for the potential long-term rewards.

Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging

A wave of biotechs is making the milestone move from drug developer to drug marketer, but investors are less interested than ever in sticking around for the potential long-term rewards.

Related Content

Topics

UsernamePublicRestriction

Register

PS072656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel